Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
small molecule
|
| gptkbp:alsoKnownAs |
Navoximod
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1204669-58-8
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
gptkb:Genentech
|
| https://www.w3.org/2000/01/rdf-schema#label |
GDC-0919
|
| gptkbp:intendedUse |
immunotherapy
|
| gptkbp:mechanismOfAction |
IDO1 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
Indoleamine 2,3-dioxygenase 1 (IDO1)
|
| gptkbp:UNII |
6Q1K1QF0X1
|
| gptkbp:bfsParent |
gptkb:navoximod
|
| gptkbp:bfsLayer |
8
|